Your browser doesn't support javascript.
Attitudes Towards Vaccination for Coronavirus Disease 2019 in Patients with Severe Alpha-1 Antitrypsin Deficiency.
McElvaney, Oliver J; Cleary, Brian; Fraughen, Daniel D; Kelly, Geraldine; Murphy, Mark P; McElvaney, Oisín F; Branagan, Peter; Gunaratnam, Cedric; Carroll, Tomás P; McElvaney, Noel G.
  • McElvaney OJ; Department of Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland.
  • Cleary B; Beaumont Hospital, Dublin, Ireland.
  • Fraughen DD; Alpha-1 Foundation of Ireland, Dublin, Ireland.
  • Kelly G; Beaumont Hospital, Dublin, Ireland.
  • Murphy MP; Department of Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland.
  • McElvaney OF; Beaumont Hospital, Dublin, Ireland.
  • Branagan P; Alpha-1 Foundation of Ireland, Dublin, Ireland.
  • Gunaratnam C; Alpha-1 Foundation of Ireland, Dublin, Ireland.
  • Carroll TP; Department of Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland.
  • McElvaney NG; Department of Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland.
Chronic Obstr Pulm Dis ; 9(2): 266-273, 2022 Apr 29.
Article in English | MEDLINE | ID: covidwho-1856402
ABSTRACT
Patients with severe alpha-1 antitrypsin deficiency (AATD) are at increased risk for the development of chronic obstructive pulmonary disease (COPD), particularly if they smoke. This, coupled with their predilection for dysregulated inflammation and autoimmunity, makes affected individuals priority candidates for vaccination against coronavirus disease 2019 (COVID-19). To promote vaccine uptake effectively, an understanding of the factors motivating people to proceed with vaccination is essential. The attitudes of patients with AATD towards COVID-19 vaccination have yet to be described. We prospectively studied 170 Pi*ZZ genotype AATD patients, 150 patients with nonhereditary (Pi*MM genotype) COPD and 140 Pi*MM genotype individuals without lung disease receiving first-dose vaccination with ChAdOx1 nCoV-19 (AstraZeneca). Patient attitudes towards vaccination and motivations for getting vaccinated were assessed at the time of the vaccine being offered. Following completion of the 2-dose vaccine series, Pi*ZZ patients were then re-assessed regarding their attitudes towards booster vaccination. The most common primary motivation for accepting vaccination in Pi*ZZ participants ≥50 years old was a fear of illness or death from COVID-19. In contrast, Pi*ZZ patients <50 years most often cited a desire to socialize. The motivation pattern of younger Pi*ZZ AATD patients was similar to that of non-deficient individuals of comparable age, whereas older Pi*ZZ individuals were more closely aligned with Pi*MM COPD and differed from age-matched controls without lung disease. When considering booster vaccination, Pi*ZZ patients were increasingly motivated by a desire to reacquire social freedoms. A desire to reduce the risk of transmission was not a prominent consideration in any of the groups studied. The most commonly cited reason for booster hesitancy was a lack of incentive, given that no additional social freedoms were available to triple-vaccinated individuals compared to those who were double-vaccinated at the time. Taken together, these data may inform policymakers attempting to promote vaccine uptake among patients with AATD.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Topics: Vaccines Language: English Journal: Chronic Obstr Pulm Dis Year: 2022 Document Type: Article Affiliation country: Jcopdf.2022.0288

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Topics: Vaccines Language: English Journal: Chronic Obstr Pulm Dis Year: 2022 Document Type: Article Affiliation country: Jcopdf.2022.0288